140 related articles for article (PubMed ID: 18362418)
1. Rationale and design of a study to examine lower targets for low-density lipoprotein-cholesterol and blood pressure in coronary artery disease patients.
Nagai R; Izumi T; Kurabayashi M; Daida H; Tojo T; Hasegawa A; Miyauchi K; Hayashi D; Kohro T; Okada Y; Yamazaki T;
Circ J; 2008 Apr; 72(4):515-20. PubMed ID: 18362418
[TBL] [Abstract][Full Text] [Related]
2. Intensive LOwering of BlOod pressure and low-density lipoprotein ChOlesterol with statin theraPy (LOBOCOP) may improve neointimal formation after coronary stenting in patients with coronary artery disease.
Takamiya Y; Miura S; Kawamura A; Tanigawa H; Zhang B; Iwata A; Nishikawa H; Matsuo K; Shirai K; Saku K
Coron Artery Dis; 2009 Jun; 20(4):288-94. PubMed ID: 19440067
[TBL] [Abstract][Full Text] [Related]
3. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
[TBL] [Abstract][Full Text] [Related]
4. Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial.
Newman JD; Alexander KP; Gu X; O'Brien SM; Boden WE; Govindan SC; Senior R; Moorthy N; Rezende PC; Demkow M; Lopez-Sendon JL; Bockeria O; Pandit N; Gosselin G; Stone PH; Spertus JA; Stone GW; Fleg JL; Hochman JS; Maron DJ
Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e006002. PubMed ID: 31718297
[TBL] [Abstract][Full Text] [Related]
5. Intensively lowering both low-density lipoprotein cholesterol and blood pressure does not reduce cardiovascular risk in Japanese coronary artery disease patients.
Kohro T; Yamazaki T; Izumi T; Daida H; Kurabayashi M; Miyauchi K; Tojo T; Nagai R;
Circ J; 2011; 75(9):2062-70. PubMed ID: 21817806
[TBL] [Abstract][Full Text] [Related]
6. Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
Shioji K; Izuhara M; Mitsuoka H; Uegaito T; Matsuda M;
Cardiovasc Ther; 2014 Jun; 32(3):97-104. PubMed ID: 24456217
[TBL] [Abstract][Full Text] [Related]
7. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
[TBL] [Abstract][Full Text] [Related]
8. Managing dyslipidemia in the high-risk patient.
Stein EA
Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
[TBL] [Abstract][Full Text] [Related]
9. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N
J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705
[TBL] [Abstract][Full Text] [Related]
10. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
[TBL] [Abstract][Full Text] [Related]
11. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
12. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial.
Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Ono T; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
J Cardiol; 2015 Oct; 66(4):353-8. PubMed ID: 25577723
[TBL] [Abstract][Full Text] [Related]
13. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
[TBL] [Abstract][Full Text] [Related]
14. The status of lipid management in 1,836 patients with coronary artery disease: a multicenter survey to evaluate the percentage of Japanese coronary artery disease patients achieving the target low-density lipoprotein cholesterol level specified by the Japan Atherosclerosis Society.
Nagashima H; Kasanuki H
J Atheroscler Thromb; 2005; 12(6):338-42. PubMed ID: 16394618
[TBL] [Abstract][Full Text] [Related]
15. Impact of combined lipid lowering with blood pressure control on coronary plaque regression: rationale and design of MILLION study.
Kawashiri MA; Sakata K; Gamou T; Kanaya H; Miwa K; Ueda K; Higashikata T; Mizuno S; Michishita I; Namura M; Nitta Y; Katsuda S; Okeie K; Hirase H; Tada H; Uchiyama K; Konno T; Hayashi K; Ino H; Nagase K; Terashima M; Yamagishi M
Heart Vessels; 2015 Sep; 30(5):580-6. PubMed ID: 24895097
[TBL] [Abstract][Full Text] [Related]
16. Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol.
Lee SY; Oh SJ; Kim EJ; Oum CY; Park SH; Oh J; Kim JS; Kim BK; Park S; Chang HJ; Hong GR; Ko YG; Kang SM; Choi D; Ha JW; Hong MK; Jang Y; Chung N; Lee SH
PLoS One; 2016; 11(11):e0166246. PubMed ID: 27824924
[TBL] [Abstract][Full Text] [Related]
17. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
[TBL] [Abstract][Full Text] [Related]
18. Rationale and Design of Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) Trial.
Miyauchi K; Kimura T; Shimokawa H; Daida H; Iimuro S; Iwata H; Ozaki Y; Sakuma I; Nakagawa Y; Hibi K; Hiro T; Fukumoto Y; Hokimoto S; Ohashi Y; Ohtsu H; Saito Y; Matsuzaki M; Nagai R;
Int Heart J; 2018 Mar; 59(2):315-320. PubMed ID: 29503404
[TBL] [Abstract][Full Text] [Related]
19. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
Hunninghake DB
Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
